Peninsula cell therapy company's stock sheds nearly 40% after-hours as FDA halts clinical trial

A single patient in the company's mid-stage clinical trial was found with a "chromosomal abnormality."

Source: bizjournals.com Health Care:Biotechnology headlines - October 7, 2021 Category: Biotechnology Authors: Ron Leuty Source Type: news